The Non-Coding RNA GAS5 and Its Role in Tumor Therapy-Induced Resistance

• Published in: International journal of molecular sciences Vol. 21; no. 20; p. 7633
• Main Authors: Lambrou, George I, Hatziagapiou, Kyriaki, Zaravinos, Apostolos
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 15-10-2020; MDPI
• Subjects: Animals; Apoptosis; Biomedical materials; Breast; Breast cancer; Cancer therapies; Cell division; Cervical cancer; Chemotherapy; DNA methylation; Drug Resistance, Neoplasm; GAS5; Gene expression; Genes, Tumor Suppressor; Genomes; Humans; invasion; Leukemia; malignancy; Metabolic disorders; Metastases; metastasis; MicroRNAs - genetics; MicroRNAs - metabolism; Neoplasms - drug therapy; Neoplasms - genetics; Non-coding RNA; Obesity; Osteosarcoma; Polymorphism; proliferation; Prostate; Proteins; Radiation therapy; Review; RNA, Long Noncoding - genetics; RNA, Long Noncoding - metabolism; Transcription; tumor growth; Tumor suppressor genes; Tumors; Urinary bladder; tumor growth; invasion; malignancy; proliferation; metastasis; GAS5
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms21207633

The growth arrest-specific transcript 5 (
) is a >200-nt lncRNA molecule that regulates several cellular functions, including proliferation, apoptosis, invasion and metastasis, across different types of human cancers. Here, we reviewed the current literature on the expression of
in leukemia, cervical, breast, ovarian, prostate, urinary bladder, lung, gastric, colorectal, liver, osteosarcoma and brain cancers, as well as its interaction with various miRNAs and its effect on therapy-related resistance in these malignancies. The general consensus is that
acts as a tumor suppressor across different tumor types and that its up-regulation results in tumor sensitization to chemotherapy or radiotherapy.
seems to play a previously unappreciated, but significant role in tumor therapy-induced resistance.